Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study.
Acute Coronary Syndrome
/ surgery
Adenosine Monophosphate
/ analogs & derivatives
Adult
Hemorrhage
/ chemically induced
Humans
Percutaneous Coronary Intervention
/ adverse effects
Platelet Aggregation Inhibitors
/ adverse effects
Prospective Studies
Purinergic P2Y Receptor Antagonists
/ adverse effects
Treatment Outcome
P2Y12 inhibitor
acute coronary syndrome
bleeding
cangrelor
cardiac artery disease
real-world evidence
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
31
05
2022
received:
15
02
2022
accepted:
03
06
2022
pubmed:
24
6
2022
medline:
11
9
2022
entrez:
23
6
2022
Statut:
ppublish
Résumé
The itAlian pRospective Study on CANGrELOr (ARCANGELO) was aimed to assess the safety of using cangrelor during percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) in the daily practice. The safety of cangrelor after the transition to oral P2Y12 inhibitors was evaluated as the incidence of bleeding outcomes in the 30 days following PCI according to postauthorization safety study guidelines. Adults with ACS who were treated with cangrelor in one of the 28 centers involved in the study. Patients who consented to participate were followed in the 30 days following their PCI. Bleedings (Bleeding Academic Research Consortium [BARC] classification), major adverse cardiac events (MACEs), and adverse events were recorded. The interim results at two-thirds of the enrollment period are presented. A total of 17 bleedings were observed in the 320 patients who completed the study at this stage. All bleedings were classified as BARC Type 1-2, except for one case of Type 3a (vessel puncture site hematoma). Four patients experienced MACEs (2 acute myocardial infarctions, 1 sudden cardiac death, 1 noncardiovascular death due to respiratory distress, and multiorgan failure). None of the bleedings was rated as related to cangrelor. The interim results of the ARCANGELO study provide a preliminary confirmation that the use of cangrelor on patients with ACS undergoing PCI is not associated with severe bleedings.
Sections du résumé
BACKGROUND
BACKGROUND
The itAlian pRospective Study on CANGrELOr (ARCANGELO) was aimed to assess the safety of using cangrelor during percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) in the daily practice.
HYPOTHESIS
OBJECTIVE
The safety of cangrelor after the transition to oral P2Y12 inhibitors was evaluated as the incidence of bleeding outcomes in the 30 days following PCI according to postauthorization safety study guidelines.
METHODS
METHODS
Adults with ACS who were treated with cangrelor in one of the 28 centers involved in the study. Patients who consented to participate were followed in the 30 days following their PCI. Bleedings (Bleeding Academic Research Consortium [BARC] classification), major adverse cardiac events (MACEs), and adverse events were recorded. The interim results at two-thirds of the enrollment period are presented.
RESULTS
RESULTS
A total of 17 bleedings were observed in the 320 patients who completed the study at this stage. All bleedings were classified as BARC Type 1-2, except for one case of Type 3a (vessel puncture site hematoma). Four patients experienced MACEs (2 acute myocardial infarctions, 1 sudden cardiac death, 1 noncardiovascular death due to respiratory distress, and multiorgan failure). None of the bleedings was rated as related to cangrelor.
CONCLUSIONS
CONCLUSIONS
The interim results of the ARCANGELO study provide a preliminary confirmation that the use of cangrelor on patients with ACS undergoing PCI is not associated with severe bleedings.
Identifiants
pubmed: 35733352
doi: 10.1002/clc.23878
pmc: PMC9451664
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Adenosine Monophosphate
415SHH325A
cangrelor
6AQ1Y404U7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
913-920Informations de copyright
© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
Références
Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):352-359
pubmed: 33175148
Cardiol Rev. 2017 May/Jun;25(3):133-139
pubmed: 28379902
Circ Cardiovasc Interv. 2022 Jan;15(1):e010390
pubmed: 34915723
Expert Rev Cardiovasc Ther. 2019 Oct;17(10):717-727
pubmed: 31583920
TH Open. 2020 Dec 23;4(4):e437-e445
pubmed: 33376943
J Cardiovasc Med (Hagerstown). 2017 Aug;18(8):580-589
pubmed: 28639987
Drugs. 2015 Aug;75(12):1425-34
pubmed: 26201463
Panminerva Med. 2022 Mar;64(1):9-16
pubmed: 34060281
JAMA. 2004 Nov 3;292(17):2096-104
pubmed: 15523070
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Practitioner. ;260(1797):19-23
pubmed: 29016088
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):151-157
pubmed: 30698669
Eur Heart J Acute Cardiovasc Care. 2015 Oct;4(5):441-52
pubmed: 25414322
Nat Rev Cardiol. 2013 Mar;10(3):121-2
pubmed: 23319096
JAMA Cardiol. 2019 Nov 1;4(11):1092-1101
pubmed: 31557763
Am Heart J. 2012 May;163(5):768-776.e2
pubmed: 22607853
J Am Heart Assoc. 2021 Jul 6;10(13):e022125
pubmed: 34212768
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
N Engl J Med. 2009 Dec 10;361(24):2330-41
pubmed: 19915222
Int J Cardiol. 2016 Nov 15;223:848-851
pubmed: 27580219
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Future Cardiol. 2020 Mar;16(2):89-102
pubmed: 32067479
Clin Cardiol. 2022 Sep;45(9):913-920
pubmed: 35733352
J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228
pubmed: 25260718
N Engl J Med. 2013 Apr 4;368(14):1303-13
pubmed: 23473369
JAMA. 2005 Jun 15;293(23):2908-17
pubmed: 15956636
JACC Cardiovasc Interv. 2017 Aug 28;10(16):1712-1714
pubmed: 28838482
JACC Cardiovasc Interv. 2010 Jun;3(6):571-83
pubmed: 20630450
J Am Coll Cardiol. 2017 Jan 31;69(4):463-464
pubmed: 27914699
Expert Rev Cardiovasc Ther. 2009 Oct;7(10):1195-201
pubmed: 19814662
J Am Coll Cardiol. 2006 Oct 3;48(7):1319-25
pubmed: 17010789
Thromb Res. 2008;122(6):776-81
pubmed: 18455217
Eur J Clin Pharmacol. 2013 Mar;69(3):309-17
pubmed: 22890586
J Clin Pharmacol. 2010 Jan;50(1):27-35
pubmed: 19779037